Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Novo Nordisk ( (NVO) ).
On 4 February 2026, Novo Nordisk launched a DKK 15 billion, 12‑month share repurchase programme under EU Safe Harbour rules, including up to DKK 3.8 billion of B‑share buybacks scheduled between 4 February and 4 May 2026. Between 13 and 17 April 2026, the company bought an additional 1,250,000 B shares, bringing total purchases since 4 February to 12,257,992 B shares at an average price of DKK 256.87 and lifting treasury holdings to 28,397,791 B shares, or 0.6% of its share capital.
As of 17 April 2026, Novo Nordisk had deployed about DKK 3.15 billion toward the ongoing buyback, signalling continued capital returns to shareholders alongside its core investment in chronic disease therapies. The programme, disclosed in a 20 April 2026 filing, underscores Novo Nordisk’s confidence in its long‑term prospects and provides incremental support to its share price while modestly reducing free float over the course of the repurchase period.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases with a heritage in diabetes care. It employs about 68,800 people in 80 countries, markets its medicines in around 170 countries, and its B shares trade on Nasdaq Copenhagen while its ADRs list on the New York Stock Exchange.
Average Trading Volume: 22,793,957
Technical Sentiment Signal: Sell
Current Market Cap: $176.8B
Learn more about NVO stock on TipRanks’ Stock Analysis page.
